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Abstract
Background: Environmental factors, particularly commensal bacteria in the gastrointestinal tract, may be involved
in the pathogenesis of rheumatoid arthritis (RA). The aim of this study was to evaluate whether natural milk
antibodies against a wide spectrum of pathogenic enteromicobes and their toxins modify the disease activity in
RA.
Methods: Twenty patients with RA, whose disease activity was uncontrolled by authentic medications due to drug
resistance, complications and/or risk factors were treated for 3 months with an oral administration of a whey
protein concentrate (WPC) containing high levels of natural milk antibodies. Eighteen background-matched RA
patients, not supplemented with milk antibody adjunct, were used as controls.
Results: Statistically significant reduction of arthritis symptoms and improvement of intestinal disorders were
observed only in the test group: effective in 8 (44%), possibly effective in 2 (12%) and not effective in 8 (44%) of 18
patients treated (2 patients withdrew) based on an ad hoc “evaluation point”, the sum of variables that are
improved more than 20% among the 8 core variables used for the American College of Rheumatology (ACR)
response criteria. This disease modifying effect of the WPC disappeared upon cessation of treatment, but was
reappeared upon reintroduction of it. Importantly, 7 of 8 non-responders carry DR15 haplotype (DRB1-1501 and
1502), whereas only 1 of 7 responders was DR15 positive (risk ratio: 6.1). Furthermore, the pre-clinical serum anti-
LPS and anti-type II collagen antibody levels in the responders were higher or tended to be higher than those in
the non-responders, suggesting that there are 2 sub-types of RA based on an interaction between gastrointestinal
pathogens and MHC class II haplotypes.
Conclusions: The natural milk antibody preparation containing high levels antibodies against pathogenic
enteromicrobes and their toxins seems to be effective in a certain RA subset, and deserves more attention as a
potential adjunct in the treatment of RA.
Trial Registration Number: UMIN000003128
Background
The disease causative factor of rheumatoid arthritis (RA)
remains unknown regardless of extensive studies on
candidate antigens [1-5] and disease susceptibility [6,7].
Recently, some consideration has been given to environ-
mental factors, particularly commensal bacteria in the
gastrointestinal (GI) tract [8,9]. For example, it has been
shown that bacterial cell wall components, such as
enterobacterial common antigens [10] and peptidogly-
can-polysaccharide polymers, can induce arthritis
[11,12] and uveitis [13] in experimental animals. GI bac-
teria and their toxins such as lipopolysaccharides (LPS:
gram-negative bacteria cell wall components) apparently
contribute to the development and exacerbation of auto-
immune diseases in experimental models such as auto-
immune thyroiditis in rats [14] and autoimmune
hemolytic anemia (AIHA) in mice [15,16].
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mensal bacteria may play a pathogenic role in patients
with RA. Aoki et al. reported that some patients with RA
were sensitized to enterobacterial common antigens (35
and 38 kDa outer membrane protein) [10]. Van der
Heijden and coworkers reported that degradation pro-
ducts of bacterial cell walls and nucleic acids were found
in RA joints [17]. Imbalance of intestinal bacteria has
even been suggested as a possible etiopathogenic or
aggravating factor in RA based on the observation that
modulation of the intestinal bacterial flora by a vegetar-
ian diet was associated with clinical improvement
[18-20]. Unfortunately, these observations were not
acknowledged by researchers in the fields of immunology
and rheumatology, because of the difficulty of handling
and analyzing intestinal bacteria. However, Vaahtovuo
et al. [21] recently reported that Bifidobacteria, bacteria of
the Bacteroides-Porphyromonas-Prevotella group, Bacter-
oides fragilis subgroup, and Eubacterium rectale-Clostri-
dium coccoides group were significantly less numerous in
early RA than in controls as determined by flow cytometry
analysis of 16 S rRNA hybridized and DNA-stained fecal
bacteria.
Based on our [4,5,22,23] and other previous studies
[24], it has been hypothesized that the increased perme-
ability of the GI mucosa relating to a lowered immune
function of gut associated lymphoid tissues (GALT)
could modulate rheumatoid disease activity [25]. For
example, excess amounts of bacteria toxins absorbed
from the GI mucosa may directly stimulate the release
of pro-inflammatory cytokines such as tumour necrosis
factor (TNF), interleukin-1 (IL-1) [26], and high mobility
g r o u pb o x - 1( H M G B 1 )p r o t e i n[ 2 7 ] ,w h i c hc o u l d
exacerbate inflammatory reactions [23,28,29], but also
systemically affect the host’s immune system for pro-
longed periods as non-specific immunostimulants.
The GI bacterial balance is modulated by interactions
between pathogenic and non-pathogenic bacteria and by
the host’s immune function. Therefore, it is rational to
consider how to alter or normalize intestinal environmen-
tal conditions by foods rather than antibiotics, since it is
apparent that nutritional components apparently affect the
intestinal bacterial flora population. In this aspect, we
focused on natural milk antibodies, which recognize a
wide spectrum of pathogenic entromicrobes and their tox-
ins. Accordingly, we prepared a whey protein concentrate
(WPC), which contains high levels of bioactive natural
antibodies [30], from normal cow milk instead of colos-
trums using special conditions to avoid heat denaturation
of immunoglobulins. This WPC was tested in elderly
volunteers, and the test results clearly indicated that bioac-
tive natural milk antibody preparation is capable of modu-
lating intestinal bacterial flora, e.g. decreasing the
population of E. coli and Clostridium perfringens (formally
known Clostridium welchii) by 50 and 80% respectively in
the feces, whereas increasing the population of Lactbacilli
3-fold (Iwatsuki eta al: manuscript submitted). Based on
these observations, in this study, we evaluated the disease
modifying effect of this WPC in patients with RA. The
results in this open labelled interventional study could
shed light on the eventual involvement of enteromicrobes
and their toxins in RA, prior to an eventual large-scale
double blind controlled study.
Methods
Patients
This study (the trial registration number:
UMIN000003128) was approved by the ethical commit-
t e eo fK a t a y a m aO r t h o p e d i cR h e u m a t o l o g yC l i n i c ,a n da
written informed consent was obtained from all patients
before performing any study procedures according to the
Declaration of Helsinki. Thirty-eight voluntary patients
with RA attending the Katayama Orthopedic Rheumatol-
ogy Clinic and fulfilling the ACR diagnostic criteria of
RA [31] were enrolled in this quasi-randomized study
based on problems with authentic medications due to
drug resistance, complications and/or risk factors. All
patients continuously received the current treatments
through this test period. The first twenty patients meet-
ing the selection criteria received a whey protein product
containing active antibodies in addition to their current
medication (test group). The next 18 background-
matched patients visiting the clinic were used as controls
without administration of this supplement (control
group). Eighteen out of 20 patients in the test group
completed the study: 1 man and 17 women, average age
59.7 (range 31-80) years and average disease duration of
114.5 (range 3-360) months. Reasons for inclusion were
resistance to concomitant drug therapy (5 patients), drug
allergies (4), or complications and/or risk factors (9),
such as interstitial pneumonitis (1), bilateral severe knee
flexion contracture (1), cancer chemotherapy (2), breast-
feeding (1), leucocytopenia (1), chronic heart failure (1),
severe osteoporosis (1) and previous pneumonia (1).
Mean prednisolone dose in the test group was 2.64 mg/
day and mean 28 joint count disease activity score using
ESR (DAS28-ESR) was 5.64 at the entry.
The eighteen background-matched control patients
consisted of 1 man and 17 women, average age 62.8
(range 44-88) years and average disease duration of 88.1
(range 9-336) months. Mean prednisolone dose in this
group was 2.72 mg/day, and mean DAS28-ESR at entry
was 5.64. The basic pre-clinical data of patients in these
2 groups are shown in Table 1.
Administration of milk antibody
In the test group, one 10 g package of whey protein con-
centrate containing natural milk antibodies (Bonyuno
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ment daily after breakfast for 3 months, whereas control
patients did not get this food supplement.
In 5 patients (ID 198, 3188, 3709, 3240 and 4119),
who responded to this milk antibody treatment as
described later, the treatment was repeated after cessa-
tion to assess the eventual effect of recall treatment. In
addition, 1 patient (ID3240) volunteered for the 3rd
time treatment.
Whey protein
A whey protein product, Bonyuno Chikara®, was sup-
plied by Asama Chemicals Inc. Tokyo, Japan. This pro-
duct was prepared from normal cow milk instead of
colostrums using special conditions to avoid heat dena-
turation of immunoglobulins, and has been shown to
contains relatively high levels of active antibodies against
at least 33 strains of pathogenic bacteria [30]. One 10 g
packet contains 6 g of whey protein concentrate con-
tains 240 mg natural immunoglobulins, equivalent to
5 0 0 - 6 0 0m lo fr a wm i l k ,a n d3gof fructooligosacchar-
ide, 0.8 g of milk calcium, and 0.2 g of cellulose.
Clinical assessments
All patients in the test group were evaluated every
month during the 3-month treatment period, whereas
patients in the control group were evaluated before and
after 3 months using the ACR response criteria with 7
core set variables: acute phase reactants (C-reactive pro-
tein: CRP or erythrocyte sedimentation rate: ESR), 0-66
swollen joint count (SJC), 0-68 tender joint count (TJC),
modified Health Assessment Questionnaire (mHAQ),
patient’s and physician’s global assessment of disease
activity by visual analogue scale (VAS), and patient’s
pain assessment by VAS [32], and the European League
Against Rheumatism (EULAR) response criteria using
DAS28-ESR [33].
However, the ACR response criteria were not consid-
ered to be appropriate for evaluating the indirect disease
modifying effects of milk antibodies, which do not pos-
sess direct anti-inflammatory or analgesic actions.
Therefore, the effect of milk antibody treatment was
evaluated by using an ad hoc “Evaluation Point”,w h i c h
was set up for the descriptive purposes of this study.
For this analysis, the 7 core set variables used in the
ACR response criteria were divided into 8 variables by
separating the acute phase reactants into 2 variables,
CRP and ESR, to evenly emphasize the importance of
these independent marker values. The sum of the vari-
ables, which gained more than 20% improvement, was
d e f i n e da sa ne v a l u a t i o np o i n t .E v a l u a t i o np o i n t so f3
out of 8 and over were considered to be effective and
defined as responders, whereas evaluation points of 2
and under were considered to be not effective and
defined as non-responders. In addition, individual
patients were further evaluated for features not related
to arthritis but to general health, such as GI status,
appetite, weight gain, activities of daily living (ADL),
anemia, fatigue, sleep and daily physical feeling, and
required dosage of steroid or NSAID.
Biological serum markers
Serum TNF and IL-6 levels were determined using
ELISA kits for human TNF-a/TNSF1A and human IL-6
(R & D Systems, Minneapolis, MN, USA). Serum anti-
body levels against human, bovine and chicken type II
collagen, and LPS from E. coli O26, O55 and O111
(Sigma-Aldrich, St. Louis, MO, USA) were assayed by
ELISA as previously reported [4]. Briefly, ELISA plates
were coated with antigen (5 μg/ml) dissolved in phos-
phate buffer (μ = 0.4), pH 7.6. Antigen non-coated wells
were used as a blank to determine background values of
Table 1 Comparison of baseline clinical demographics of
test and control groups
Control Group Test Group P
Categories (N = 18) (N = 18)
Clinical assessment at entry
Age (Years) 62.8 ± 11.4 59.7 ± 14.9 NS
†
RA duration (Months) 88.1 ± 76.2 114.5 ± 92.6 NS
†
DAS28-ESR 5.64 ± 0.86 5.64 ± 1.37 NS
†
TJC 12.3 ± 6.1 15.9 ± 11.7 NS
†
SJC 12.6 ± 6.2 13.9 ± 7.8 NS
†
ESR (mm/hr) 46.7 ± 27.0 48.4 ± 32.9 NS
†
CRP (mg/dl) 2.5 ± 2.4 2.5 ± 2.8 NS
†
RF (IU/ml) 143 ± 102 213 ± 292 NS
†
Medication
PSL (mg/day) 2.72 ± 2.29 2.64 ± 2.94 NS
†
PSL (No.) 13 11 NS
§
DMARDs (No.) 16 13 NS
§
NSAIDs (No.) 14 11 NS
§
Ochi’s Classification
LES 3 (17%) 4 (22%) NS
§
MES 12 (66%) 10 (56%) NS
§
MUD 3 (17%) 4 (22%) NS
§
Complications and risk factor
Complication (No.) 9 9 NS
§
Drug resistance (No.) 7 5 NS
§
Drug allergy (No.) 2 4 NS
§
Gastrointestinal Disorders
Constipation (No.) 12 12 NS
§
Diarrhea (No.) 3 2 NS
§
None (No.) 3 4 NS
§
Data is shown as the mean ± standard deviation.
TJC: tender joint count, SJC: swollen joint count, RF: rheumatoid factor, PSL:
Prednisolone, LES: least erosive subset, MES: more erosive subset, MUD:
mutilating disease, NS: Not significant.
†: Determined by Mann Whitney U-test. §: Determined by Chi square test.
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serum, pH 8.0, was used for blocking and sample dilu-
tion [4]. The secondary antibodies, biotin-conjugated
goat anti-human IgG and IgA antibodies (Sigma, USA),
were diluted in 2% normal goat serum, whereas strepta-
vidin-peroxidase was diluted in 2% milk casein hydroly-
sate dissolved in 0.1 M Tris-HCl buffer, pH 7.5. All
serum samples were diluted 1:100 and incubated with
antigens at room temperature for 2 hours. Colour was
developed using tetramethylbenzidine (TMB), and opti-
cal density (OD) values of antigen non-coated wells
(blank values) of individual samples were subtracted
from the OD values in antigen-coated wells.
For the anti-LPS antibody assay, affinity-purified
bovine IgG anti-E. coli O111 LPS antibody was used as
a reference to compare OD values in the same plate.
For detection of bovine anti-LPS antibody, biotinylated
goat anti-bovine IgG antibody (Jackson ImmunoRe-
search, West Grove, PA, USA) was used. Antibody con-
centrations in human serum samples are expressed as
μg/ml.
HLA typing
HLA types were analyzed using peripheral blood cells
collected from individual patients by rssop method at
HLA Laboratory, Kyoto, Japan.
Statistical analysis
Data is expressed as the mean ± standard deviation except
if otherwise indicated. For statistical evaluation, the paired
Student’s t-test was used to determine the significance of
differences before and after treatment. The Mann-Whit-
ney U-test was used for comparisons between the control
and test groups, and the responder and non-responder
groups. Chi-square test with Fisher’s exact probability test
was used for analysis of incidence and prevalence data.
Results are shown using P values with 5% level of signifi-
cance if not otherwise stated. The relationship of HLA
haplotypes and therapeutic effect of milk antibodies was
analyzed by a prospective cohort analysis using an equa-
tion, Relative risk = [a/(a+b)]/[c(c+d)], whereas a: number
of patients with DR15+ (non-responder), b: DR15+
(responder), c: DR15- (non-responder), and d: DR15-
(responder).
Results
Clinical demographics of patients in test and control
groups
Baseline clinical demographics of the test and control
groups were similar (Table 1). Based on the number of
milk packages returned at the monthly controls, compli-
ance with taking the whey protein was high, and only 2
of 20 patients withdrew due to disliking of the milk fla-
vour. One patient (ID3188) reported aggravated
constipation during the second treatment period, but
otherwise no adverse effects were reported.
Evaluation of disease modifying effect of milk
antibody treatment
Apparent improvement of disease marker values such as
CRP and SJC was observed as early as 1 month in sev-
eral patients in the test group and lasted until the end
of the study, where such changes were not seen in the
control group. After 3-months of treatment, all patients
were evaluated by 3 methods, the evaluation point,
ACR, and EULAR response criteria (Table 2), in addi-
tion to general health assessment by both the patient
and physician (see remarks in Table 2).
By the evaluation point analysis, milk antibody treat-
ment was considered to be effective (evaluation point: 3
and more) in 8 of 18 (44.4%) patients but not effective
(evaluation point: fewer than 2) in 10 of 18 (55.6%)
patients in the test group. On the other hand, no
improvement was observed in18 control patients during
this 3-months test period, except 1 patient scored 3
(data not shown). Among 10 patients with on evaluation
point less than 2 in the test group, 2 patients (ID169
and 511) with mutilating disease and diagnosed as most
functionally severe subtype of RA by Ochi’s classification
[34] were classified as partial responders, because clini-
cal and general health parameters were apparently
improved as shown in “ Remarks” in Table 2.
Among the 8 patients classified as responders by the
evaluation point, 2 patients improved by 20% (ACR20)
and 1 patient by 50% (ACR50) according to the ACR
response criteria, whereas DAS28-ESR improvement was
good in 1 patient, moderate in 4 patients, and poor in 3
patients by EULAR response criteria as shown in Table
2. None of the 2 partial responders, 8 non-responders
and 18 control patients showed improvement by either
ACR or EULAR evaluation.
General health assessment was performed by both the
patient and physician for fatigue, anemia, mobility, ADL,
appetite, and GI status such as constipation and diar-
rhea (see Remarks in Table 2). Notably, constipation or
diarrhea was observed in 12 and 3 patients out of 18
patients, respectively, in the control group, and 12 and 2
patients out of 18 patients in the test group (Table 1).
In the test group, these symptoms were alleviated in 11
of 14 patients: 7 of 7 responders, 1 of 1 (ID 511) partial
responder, and even in 3 of 6 patients (ID 721, 2264 &
9291) in the non-responder group, but in none of the
15 patients in the control group (P < 0.01).
Effect of milk antibody treatment on clinical marker
values
The temporal changes of the 8 core variables during the
treatment with milk antibody are shown in Figure 1 to
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ders in the test group and non-treated patients in the
control group. In the control group, ESR (p < 0.05) and
TJC (p < 0.01) increased due to the persistence of the dis-
ease during the 3-month period. In contrast, the mean
values of all 8 variables declined or tended to decline in
responders of the test group, whereas all these values
tended not to change or increase in non-responders. The
most remarkable and steady improvement was observed
in CRP and SJC, although significant improvement was
also observed in the other 4 variables, ESR, patient’sp a i n
assessment, and patient’s and physician’s global health
assessments by VAS at the end of the 3-month treatment.
Associated with these trends, the mean of DAS28 values
in the control group and the non-responder group
increased or tended to increase from 5.64 ± 0.86 to 6.29
± 0.94 (p < 0.05) and 5.45 ± 1.44 to 6.18 ± 1.15 (NS),
whereas DAS28 values in the responder group decreased
from 5.63 ± 1.26 to 4.66 ± 1.43 (p < 0.01) (Table 2).
Confirmation of disease modifying effect of milk
antibody treatment
Five patients from the responder group (ID198, 3188,
3709, 3240 and 4119) volunteered an additional
3-months of treatment after a 4-month washout period.
CRP and ESR levels had decreased and remained at low
levels during the first treatment period, but gradually
increased and reached the pre-treatment levels approxi-
mately 2 months after discontinuation (Figure 2a and
2b). During the second treatment period, CRP and ESR
levels decreased again, but increased after termination of
the treatment. Similarly, TJC and SJC values tended to
improve during the second treatment (the mean of TJC
value decreased from 12.4 to 9.6, and the mean of SJC
Table 2 Evaluation of therapeutic effect of milk antibody treatment in 18 patients in test group.
Patient
ID
Eval
Point
1)
ACR
2)
Criteria
DAS28-ESR Remarks of improvements DRB1-
Allele
Pre Post Δ EULAR
3) GI
4) General condition
5)
Responders
3709 8 20 6.01 3.47 2.54 Moderate C (+) Fatigue, Anemia, Weight loss 0101 0405
3188 8 20 6.31 4.82 1.49 Moderate C (+) ADL 0405 0404
4119 6 50 4.61 3.39 1.22 Moderate (/) Range of motion 0901 1406
198 6 <20 8.02 7.13 0.89 No C (+) Fatigue, Anemia 0803 1401
5284 5 <20 4.32 3.07 1.25 Good C (+) Unhealthy feeling 0410 1502
10572 3 <20 6.12 6.08 0.04 No C (+) Appetite, Sleep 1302 1406
1316 3 <20 4.34 4.21 0.13 No C (+) Fatigue ND ND
3240 3 <20 5.29 4.63 0.66 Moderate D (+) Unhealthy feeling 0405 1202
Ave 5.3 ± 2.1 5.63 ± 1.26 4.66 ± 1.43 0.97 ± 0.87 (7/7)
Pre vs. Post P < 0.01 P < 0.01
Partial responders
169 2 <20 5.26 6.22 -0.96 No (/) Fatigue, Intra-articular effusion 0901 -
511 1 <20 8.15 7.85 0.30 No D (+) Range of motion 0405 1101
Ave 1.5 ± 0.7 6.75 ± 2.10 7.04 ± 1.15 -0.33 ± 0.89 (1/1)
Non-Responders
9291 2 <20 4.70 5.04 -0.34 No C (+) - 0803 1501
3007 1 <20 4.44 5.85 -1.41 No (/) - 1101 1502
2264 1 <20 8.00 7.86 0.14 No C (+) - 0405 -
721 1 <20 6.33 6.29 -0.04 No C (+) - 0405 1501
7785 0 <20 6.22 7.58 -1.36 No C (-) Edema at lower thigh 0901 1501
2110 0 <20 ND ND ND ND C (-) - 0405 1502
8861 0 <20 4.01 5.68 -1.67 No C (-) - 0901 1501
10164 0 <20 4.45 4.94 -0.49 No (/) - 0405 1501
Ave 0.6 ± 0.7 5.45 ± 1.44 6.18 ± 1.15 -0.73 ± 0.74 (3/6)
Pre vs. Post NS NS
Responder vs. Non-Responder NS P < 0.05
1) Number of categories among 8 categories gained more than 20% improvement. 2) American College of Rheumatology, 3) European League Against
Rheumatism response criteria using DAS28-ESR. 4) Gastrointestinal disorder, C: Constipation, D: Diarrhea, (+): improved, (-): not improved, (/): no GI disorder. 5)
ADL: activities of daily living.
ND: Not determined, NS: Not significant.
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decrease during the second treatment (Figure 2c), except
in 1 patient (ID 3188) whose constipation worsened
during the second treatment period.
Differences between responders and non-responders to
milk antibody treatment: possible contribution of DR15
Haplotype
In order to search for the fundamental difference
between the responders and the non-responders, the
pre-clinical biological marker values before starting this
treatment were compared (Figure 3). There were no sig-
nificant differences in serum TNF-a and IL-6 levels,
which represent the inflammatory reactions. However,
anti-human type II collagen antibody levels in the
responder group were higher than those in the non-
responder group (P < 0.05). Similarly, serum IgG and
IgA anti-LPS antibody levels tended to be higher or
were higher in the responder group compared to the
non-responder group (IgG: P = 0.052, IgA: P < 0.05) as
shown in Figure 3.
Notably, only 1 of 7 responders who had been tested
for their HLA type was positive for the DR15 (DRB1-
1501 & 1502) haplotype, whereas 7 of 8 non-responders
carried DR15 (P < 0.05). The risk factor value of DR15,
calculated by a prospective cohort analysis, was 6.1 for
non-responsiveness (p < 0.01 by Fisher’s exact test),
whereas the risk factor value of DR4 (DRB1-0404 &
0405) was 0.88 (Table 2).
Discussion
Various milk antibody products produced from immune
and normal colostrums have been previously tested as
food supplements for the treatment of infectious diar-
rhea in newborn farm animals, human infants, and
patients with AIDS (see reveiw [35]). Based on our pre-
vious obsevations that milk antibodies may prevent the
overgrowth of pathogenic bacteria and subsequently
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Figure 1 Comparison of clinical marker value changes between responder and non-responder groups. Eight variables used for ACR
response criteria were determined every month, and the average values for responder (<< ocirc >>) and non-responder (<< ccirc>>) group
were plotted. The average values for non-treated controls (<< osq >>) at 0 and 3 month were also shown for comparison. Bar: Average ± SE, *:
P < 0.05, **: P < 0.01
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Figure 2(a) (b) and (c). Due to abnormal CRP and ESR values in one patient (ID4119) at the 3rd month of the second treatment, the average
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effect of milk antibodies on the disease activity in patients
with RA. In the present study, we found that milk anti-
body treatment was associated with clinical improvement
in 10 out of 18 patients with RA, which was uncontrolla-
ble by current therapeutics due to drug resistance, com-
plications and risk factors. In the responder group, CRP
and ESR values were significantly decreased and
remained at low levels during and even 1 month after the
termination of treatment, suggesting perhaps a disease
modifying rather than placebo effect. More importantly,
use of natural antibodies was associated with alleviation
of GI disorders in most of the cases, 11 of 14 patients
with GI disorders in the test group. Especially, all 7 of 7
responders with GI disorder displayed the improvment of
GI disorders, which was associated with improvement of
a r t h r i t i sa n db i o l o g i c a lm a r k e r ss u c ha sC R Pa n dE S R .
However, in non-responder group, no apparent improve-
ment of arthritis symptom was observed in 3 patients
regardless of improvement of GI disorders, indicating
that other internal or external factors may be involved in
the pathogenesis of RA or simply the dose of milk antibo-
dies (240 mg as immunoglobulin) used in this study was
not sufficient.
Since most of the patients enrolled in this study were
elderly (60 ± 15 years old), it is likely that their intest-
inal bacteria flora balance was subject to overgrowth of
certain strains of potentially pathogenic bacteria due to
the lowered immune function at GALT associated with
immunosenescence, which may contribute in their non-
responsiveness to kefir, an immunostimulant, as shown
in rats [36]. In young adult rats, kefir enhanced immune
responses to intraduodenumly inoculated cholera toxin,
but kefir was not effective in elderly rats. Based on the
evidence that the majority of patients suffering from
gastrointestinal disorders and related diseases are
elderly, milk antibodies which directly affect the intest-
inal bacteria is considered to be more superior than
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dies on the effect of milk antibody treatment on intest-
inal bacteria flora in 47 elderly volunteers, which clearly
showed that milk antibody treatment significantly
reduced the population of E. Coli, Clostridium perfrin-
gens, Clostridium difficile, Clostridium subcluster XIVa
OTU369 and Bacteroides OTU853, whereas it increased
the population of Lactobacillus, Bacterides fragilis, gen-
era of Bacteroides and Prevotella, Clostridium subcluster
XIVa OTU995, Bacteroides OTU366, and an unidenti-
fied species of OTU443 (Iwatsuki et al, submitted).
Importantly, it has been suggested that bovine immuno-
globulins were partially resistant to proteolytic digestion
in the human stomach and small intestine [37]. Indeed,
approximately 800 μg (0.24%) of 320 mg of bovine
immunoglobulin was recovered in feces from these
volunteers. These observations coincide and are in
agreement with previous observations that vegetarian
diet altered the intestinal bacterial flora in patients with
RA [18,19] and the change in bacteria flora could affect
the outcome of disease activity.
It has been reported that translocation of bacterial
cells, cell components and toxins is increased by cold
[38], heat [39], psychological stress [40], non-steroidal
anti-inflammatory drugs [41], surgery [42] and constipa-
tion [43]. Khalif et al. reported that E. coli and S. aureus
population in the feces increased in patients with
chronic constipation, and their mucosal permeability for
heterologous proteins was increased 30-fold compared
to normal values. As a consequence, serum antibody
levels to E. coli and S. aureus were significantly
increased in these patients [43]. Via such mechanisms,
milk antibodies may indirectly reduce translocation of
bacterial toxins [42] and pathogen-associated molecu-
lules with pro-inflammatory and adjuvant effects [44],
which might affect the disease activity in RA.
In this study, we found that pre-clinical serum IgA
and IgG antibody levels to E. coli LPS (IgA: P < 0.05,
IgG: P = 0.052) and IgG anti-bovine type II collagen
antibodies (P < 0.09) were higher or tended to be higher
in the responders than the non-responders, indicating
that responders might have higher mucosal permeability
as suggested by Khalif et al [43]. In this aspect, it will be
important to notice the reports showing that some
patients with RA were sensitized by enterobacterial
common antigens (35 and 38 kDa outer membrane pro-
tein) [10], and degradation products of bacterial cell
walls and nucleic acids were found in RA joints [17].
These phenomena might be linked to genetic back-
grounds as we observed in this study that there was an
association between DR 15 negativity and responsiveness
to milk antibodies. HLA DR15 positive patients who did
not respond to the milk antibody intervention had low
antibody titer to both LPS and type II collagen. Although it
is not clear how DR15 contributes to the non-responsive-
ness to milk antibody treatment, there are potentially
2 subtypes of RA depending on an interaction between
gastrointestinal pathogens and MHC class II haplotypes. It
is possible that environmental factors are involved in the
ethiopathogenesis of autoimmune diseases, and toll-like
receptors (TLRs) that recognize molecular patterns dis-
played by microorganisms including LPS may play a
key role in activation of the innate and adaptive immune
systems [44].
Conclusions
Whey protein concentrate containing active form of nat-
ural milk antibodies seems to be a safely used food sup-
plement which has a potential to modulate autoimmune
mediated inflammatory reactions in a subset of patients
with RA. It is concluded that this pilot study encourages
future randomized controlled clinical trial to scientifi-
cally test this hypothesis.
Acknowledgements
The authors would like to thank Dr. Yrjö T. Konttinen, Professor of Medicine,
Institute of Clinical Medicine, University of Helsinki, for reading the
manuscript and providing valuable advice. We also acknowledge the
patients and nurses who participated in all studies.
Author details
1Katayama Orthopedic Rheumatology Clinic, Toyooka 13-4-5-17, Asahikawa,
Japan.
2Department of Orthopedic Surgery, Asahikawa Medical College,
Asahikawa, Japan.
3Chondrex Inc., Redmond, Washington, USA.
4Asama
Chemical Co. Ltd, Chuo-ku, Tokyo, Japan.
Authors’ contributions
KK and TM designed and conducted the clinical study, collected and
interpreted data, and wrote this report. KT and HS created and rationalized
the basic concept of this study, contributed in the designing of this trial,
interpreted the data, and wrote this report. TW analyzed and finalized the
data for publication. The corresponding author had full access to all the data
and final responsibility for the decision to submit the report for publication.
All authors read and approved the final manuscript.
Competing interests
No sources of funding were used for this study. The whey protein product,
“Bonyuno Chikara,” used in this study was supplied by Asama Chemical Co.
Ltd., Tokyo. Asama Chemical Co. Ltd., was involved in data collection and
analysis, and the study design, but had no role in data interpretation,
manuscript preparation, review, or the manuscript approval. Asama chemical
Co. Ltd., owns the pending international patents for the use of natural milk
antibodies, the main components of Bonyuno Chikara.
HS has served as a consultant for Asama Chemical Co. Ltd., received his
salary, and initiated the series of studies on bioactive natural antibodies
contained in milk, which was used for this trial. KK, KT and TW are
independent, but have been collaborating with HS on the possible
contribution of gastrointestinal disorders, which may be linked to
overgrowth of pathogenic bacteria and their toxins, particularly LPS, in the
pathogenesis of RA. TM is a collaborator with KK in clinical field for many
years, but has no relation with neither Asama chemical nor KT, TW and HS.
Received: 26 May 2010 Accepted: 6 January 2011
Published: 6 January 2011
References
1. Kaufmann SH: Heat-shock proteins: a link between rheumatoid arthritis
and infection? Curr Opin Rheumatol 1990, 2:430-5.
Katayama et al. Nutrition Journal 2011, 10:2
http://www.nutritionj.com/content/10/1/2
Page 9 of 112. Roudier J, Rhodes G, Petersen J: A Hypothesis: The Epstein-Barr virus
glycoprotein gp110, a molecular link between HLA DR4, HLA DR1, and
rheumatoid arthritis. Scand J Immunol 1988, 27:367-371.
3. Drake CG, Kotzin BL: Super Antigens: Biology, immunology, and potential
role in disease. J Clin Immunol 1992, 12:149-162.
4. Terato K, DeArmy DA, Ye XJ, Griffiths MM, Cremer MA: The mechanism of
autoantibody formation to cartilage in rheumatoid arthritis: Possible
cross-reaction of antibodies to dietary collagens with autologous type II
collagen. Clin Immunol Immunopath 1996, 79:142-154.
5. Terato K, Ye XJ, Miyahara H, Cremer MA, Griffiths MM: Induction of chronic
autoimmune arthritis in DBA/1 mice by oral administration of type II
collagen and E. coli LPS. Br J Rheum 1996, 35:828-838.
6. Gregersen PK, Silver J, Winchester RJ: The shared epitope hypothesis: an
approach to understanding the molecular genetics of susceptibility to
rheumatoid arthritis. Arthritis Rheum 1987, 30:1205-13.
7. Stastny P, Ball EJ, Khan MA, Olsen NJ, Pincus T, Gao X: HLA-DR4 and other
genetic markers in rheumatoid arthritis. Br J Rheumatol 1988, 27:132-138.
8. Toivanen P: Normal intestinal microbiota in the aetiopathogenesis of
rheumatoid arthritis. Ann Rheum Dis 2003, 62:807-11.
9. Edwards CJ: Commensal Gut Bacteria and the Etiopathogenesis of
Rheumatoid Arthritis. J Rheum 2008, 35:1477-78.
10. Aoki S, Yoshikawa K, Yokoyama T, Nonogaki T, Iwasaki S, Mitsui T, Niwa S:
Role of enteric bacteria in the pathogenesis of rheumatoid arthritis:
evidence for antibodies to enterobacterial common antigens in
rheumatoid sera and synovial fluids. Ann Rheum Dis 1996, 55:363-9.
11. Fox A, Brown RR, Anderle SK, Chetty C, Cromartie WJ, Gooder H,
Schwab JH: Arthropathic properties related to the molecular weight of
peptidegycan-polysaccharide polymers of streotococcal cell walls.
Infection Immunity 1982, 35:1003-10.
12. Sartor RB: Importance of intestinal mucosal immunity and luminal
bacterial cell wall polymers in the aetiology of inflammatory joint
diseases. Baillieres Clin Rheumatol 1989, 3:223-45.
13. Fox A, Hammer ME, Lill P, Burch TG, Burrish G: Experimental uveitis.
Elicited by peptidoglycan-polysaccharide complexes, lipopolysaccharide,
and muramyl dipeptide. Arch Ophthalmol 1986, 102:1063-7.
14. Penhale WJ, Young PR: The influence of the normal microbial flora on
the susceptibility of rats to experimental autoimmune thyroiditis. Clin
Exp Immunol 1988, 72:288-92.
15. Murakami M, Tsubata T, Shinkura R, Nisitani S, Okamoto M, Yoshioka H,
Usui T, Miyawaki S, Honjo T: Oral administration of lipopolysaccharides
activates B-1 cells in the peritoneal cavity and lamina propria of the gut
and induces autoimmune symptoms in an autoantibody transgenic
mouse. J Exp Med 1994, 180:111-21.
16. Murakami M, Nakajima K, Yamazaki K, Muraguchi T, Serikawa T, Honjo T:
Effects of breeding environments on generation and activation of
autoreactive B-1 cells in anti-red blood cell autoantibody transgenic
mice. J Exp Med 1997, 185:791-4.
17. van der Heijden IM, Wilbrink B, Tchetverikov I, Schrijver IA, Schouls LM,
Hazenberg MP, Breedveld FC, Tak PP: Presence of bacterial DNA and
bacterial peptidoglycans in joints of patients with rheumatoid arthritis
and other arthritides. Arthritis Rheum 2000, 43:593-8.
18. Peltonen R, Kjeldsen-Kragh J, Haugen M, Tuominen J, Toivanen P, Førre O,
Eerola E: Changes of faecal flora in rheumatoid arthritis during fasting
and one-year vegetarian diet. Br J Rheumatol 1994, 33:638-43.
19. Peltonen R, Nenonen M, Helve T, Hänninen O, Toivanen P, Eerola E: Faecal
microbial flora and disease activity in rheumatoid arthritis during a
vegan diet. Br J Rheumatol 1997, 36:64-8.
20. Kjeldsen-Kragh J: Rheumatoid arthritis treated with vegetarian diets. Am J
Clin Nutr 1999, 70:594S-600S.
21. Vaahtovuo J, Munukka E, Korkeamäki M, Luukkainen R, Toivanen P: Fecal
microbiota in early rheumatoid arthritis. J Rheumatol 2008, 35:1500-5.
22. Terato K, Shimozuru Y, Katayama K, Takemitsu Y, Yamashita I, Miyatsu M,
Fujii K, Sagara M, Kobayashi S, Goto M: Specificity of antibodies to type II
collagen in rheumatoid arthritis. Arthritis Rheum 1990, 33:1493-1500.
23. Terato K, Harper DS, Griffiths MM, Hasty DL, Ye XJ, Cremer MA, Seyer JM:
Collagen-induced arthritis in mice: synergistic effect of E. coli
lipopolysaccharide bypasses epitope specificity in the induction of arthritis
with monoclonal antibodies to type II collagen. Autoimmunity 1995, 22:137-147.
24. O’Mahony S, Ferguson A: Small intestinal mucosal protection
mechanisms and their importance in rheumatology. Ann Rheum Dis 1991,
50:331-6.
25. Terato K, Do C, Comstock BA, Zabrecky JR: A hypothesis: Two distinct
factors, autoantibody to type II collagen elicited by mimic antigens and
intestinal bacterial toxins, are involved independently and synergistically
in the development of autoimmune arthritis. APLAR (Asia Pacific League of
Associations for Rheumatology Congress) 2004, 11th:325-328.
26. Kagari T, Doi H, Shimozato T: The importance of IL-1 beta and TNF-alpha,
and the noninvolvement of IL-6, in the development of monoclonal
antibody-induced arthritis. J Immunol 2002, 169:1459-66.
27. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A,
Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J,
Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ: HMG-1 as a late
mediator of endotoxin lethality in mice. Science 1999, 285:248-51.
28. Yoshino S, Sasatomi E, Mori Y, Sagai M: Oral administration of
lipopolysaccharide exacerbates collagen-induced arthritis in mice.
J Immunol 1999, 163:3417-22.
29. Waritani T, Culter D, Terato K: Collagen antibody-induced arthritis in mice.
Triggering of arthritis by HMGB1, as a late stage lethal mediator of LPS.
Immunology (abstract) 2009, E72 99.22.
30. Kijima Y, Iwatsuki S, Akamatsu H, Terato K, Kuwabara Y, Ueda S, Shionoya H:
Natural antibodies to pathogenic bacteria and their toxins in whey
protein concentrate. Nippon Shokuhin Kagaku Kougaku Kaishi 2009,
56:475-482, (in Japanese).
31. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS,
Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American
Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum 1988, 31:315-24.
32. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C,
Katz LM, Lightfoot R Jr, Paulus H, Strand V, et al: American College of
Rheumatology. Preliminary definition of improvement in rheumatoid
arthritis. Arthritis Rheum 1995, 38:727-35.
33. van Gestel AM, Prevoo ML, van ‘t Hof MA, van Rijswijk MH, van de Putte LB,
van Riel PL: Development and validation of the European League
Against Rheumatism response criteria for rheumatoid arthritis.
Comparison with the preliminary American College of Rheumatology
and the World Health Organization/International League Against
Rheumatism Criteria. Arthritis Rheum 1996, 39:34-40.
34. Ochi T, Iwase R, Yonemasu K, Matsukawa M, Yoneda M, Yukioka M, Ono K:
Natural course of joint destruction and fluctuation of serum C1q levels
in patients with rheumatoid arthritis. Arthritis Rheum 1988, 31:37-43.
35. Korhonen H, Marnila P, Gill HS: Bovine milk antibodies for health. Br J Nutr
2000, 84(Suppl 1):S135-46.
36. Thoreux K, Schmucker DL: Kefir milk enhances intestinal immunity in
young but not old rats. J Nutr 2001, 131:807-12.
37. Warny M, Fatimi A, Bostwick EF, Laine DC, Lebel F, LaMont JT,
Pothoulakis C, Kelly CP: Bovine immunoglobulin concentrate-clostridium
difficile retains C difficile toxin neutralising activity after passage
through the human stomach and small intestine. Gut 1999, 44:212-7.
38. Anderlik P, Szeri I, Bános Z, Barna Z: Bacterial translocation after cold
stress in young and old mice. Acta Microbiol Hung 1990, 37:289-94.
39. Selkirk GA, McLellan TM, Wright HE, Rhind SG: Mild endotoxemia, NF-
kappaB translocation, and cytokine increase during exertional heat
stress in trained and untrained individuals. Am J Physiol Regul Integr
Comp Physiol 2008, 295:R611-23.
40. Velin AK, Ericson AC, Braaf Y, Wallon C, Söderholm JD: Increased antigen
and bacterial uptake in follicle associated epithelium induced by chronic
psychological stress in rats. Gut 2004, 53:494-500.
41. Playford RJ, MacDonald CE, Calnan DP, Floyd DN, Podas T, Johnson W,
Wicks AC, Bashir O, Marchbank T: Co-administration of the health food
supplement, bovine colostrum, reduces the acute non-steroidal anti-
inflammatory drug-induced increase in intestinal permeability. Clin Sci
(Lond) 2001, 100:627-33.
42. Bölke E, Jehle PM, Hausmann F, Däubler A, Wiedeck H, Steinbach G,
Storck M, Orth K: Preoperative oral application of immunoglobulin-
enriched colostrum milk and mediator response during abdominal
surgery. Shock 2002, 17:9-12.
Katayama et al. Nutrition Journal 2011, 10:2
http://www.nutritionj.com/content/10/1/2
Page 10 of 1143. Khalif IL, Quigley EM, Konovitch EA, Maximova ID: Alterations in the
colonic flora and intestinal permeability and evidence of immune
activation in chronic constipation. Dig Liver Dis 2005, 37:838-49.
44. Pöllänen R, Sillat T, Pajarinen J, Levón J, Kaivosoja E, Konttinen YT: Microbial
antigens mediate HLA-B27 diseases via TLRs. J Autoimmun 2009, 32:172-7.
doi:10.1186/1475-2891-10-2
Cite this article as: Katayama et al.: Supplemental treatment of
rheumatoid arthritis with natural milk antibodies against enteromicrobes
and their toxins: results of an open-labelled pilot study. Nutrition Journal 2011
10:2.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Katayama et al. Nutrition Journal 2011, 10:2
http://www.nutritionj.com/content/10/1/2
Page 11 of 11